Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples

Experimental Hematology

Volumn 42, Issue 9, 2014, Pages 816-825

  Hosoi, Masataka ^a,b   Kumano, Keiki ^a,b   Taoka, Kazuki ^a,b   Arai, Shunya ^a,b   Kataoka, Keisuke ^a,b   Ueda, Koki ^a,b   Kamikubo, Yasuhiko ^a,b   Takayama, Naoya ^c   Otsu, Makoto ^d   Eto, Koji ^c   Nakauchi, Hiromitsu ^d   Kurokawa, Mineo ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8; JANUS KINASE 2; MESSENGER RNA; IL8 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN;

ADULT; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; CHROMOSOME DELETION 13; COCULTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; JAK2 GENE; MEGAKARYOCYTE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SECONDARY MYELOFIBROSIS; AMINO ACID SUBSTITUTION; CELL CULTURE; CHROMOSOME 13; CHROMOSOME DELETION; CHROMOSOME DISORDER; CLINICAL TRIAL; FIBROBLAST; GENETICS; MALE; METABOLISM; MISSENSE MUTATION; PATHOLOGY; TERATOMA;

IPS;

ADULT; AMINO ACID SUBSTITUTION; CELLS, CULTURED; CHROMOSOME DELETION; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; COCULTURE TECHNIQUES; FEMALE; FIBROBLASTS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INTERLEUKIN-8; JANUS KINASE 2; MALE; MEGAKARYOCYTES; MIDDLE AGED; MUTATION, MISSENSE; PRIMARY MYELOFIBROSIS; TERATOMA;

EID: 84908599033     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.03.010     Document Type: Article

References (26)

1. Takahashi K., Tanabe K., Ohnuki M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
2. Maury Y., Gauthier M., Peschanski M., Martinat C. Human pluripotent stem cells for disease modelling and drug screening. Bioessays 2012, 34:61-71.
3. Cervantes F., Dupriez B., Pereira A., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
4. Verstovsek S., Mesa R.A., Gotlib J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
5. Guardiola P., Anderson J.E., Bandini G., et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999, 93:2831-2838.
6. Rondelli D., Barosi G., Bacigalupo A., et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105:4115-4119.
7. Kroger N., Zabelina T., Schieder H., et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005, 128:690-697.
8. Merup M., Lazarevic V., Nahi H., et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006, 135:367-373.
9. Wang J.C., Chang T.H., Goldberg A., Novetsky A.D., Lichter S., Lipton J. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol 2006, 34:1617-1623.
10. Chagraoui H., Komura E., Tulliez M., Giraudier S., Vainchenker W., Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002, 100:3495-3503.
11. Tefferi A., Vaidya R., Caramazza D., Finke C., Lasho T., Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011, 29:1356-1363.
12. Ciurea S.O., Merchant D., Mahmud N., et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007, 110:986-993.
13. Harrison J.S., Corcoran K.E., Joshi D., Sophacleus C., Rameshwar P. Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-beta and substance P in autoimmune myelofibrosis. Am J Hematol 2006, 81:51-58.
14. Chang V.T., Yook C., Rameshwar P. Synergism between fibronectin and transforming growth factor-beta1 in the production of substance P in monocytes of patients with myelofibrosis. Leuk Lymphoma 2013, 54:631-638.
15. Balduini A., Badalucco S., Pugliano M.T., et al. Invitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes. PLoS One 2011, 6:e21015.
16. Wang X., Prakash S., Lu M., et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest 2012, 122:3888-3899.
17. Takayama N., Nishikii H., Usui J., et al. Generation of functional platelets from human embryonic stem cells invitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 2008, 111:5298-5306.
18. Takayama N., Nishimura S., Nakamura S., et al. Transient activation of c-MYC expression is critical for efficient platelet generation fromhuman induced pluripotent stem cells. J Exp Med 2010, 207:2817-2830.
19. Ye Z., Zhan H., Mali P., et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009, 114:5473-5480.
20. Kumano K., Arai S., Hosoi M., et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 2012, 119:6234-6242.
21. Mahalingam D., Kong C.M., Lai J., Tay L.L., Yang H., Wang X. Reversal of aberrant cancer methylome and transcriptome upon direct reprogramming of lung cancer cells. Sci Rep 2012, 2:592.
22. Okabe M., Otsu M., Ahn D.H., et al. Definitive proof for direct reprogramming of hematopoietic cells to pluripotency. Blood 2009, 114:1764-1767.
23. Kuhlmann U.C., Chwieralski C.E., Reinhold D., Welte T., Buhling F. Radiation-induced matrix production of lung fibroblasts is regulated by interleukin-8. Int J Radiat Biol 2009, 85:138-143.
24. Le Bousse-Kerdiles M.C., Martyre M.C. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999, 78:437-444.
25. Dong M., Blobe G.C. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006, 107:4589-4596.
26. Skov V., Larsen T.S., Thomassen M., et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res 2012, 36:1387-1392.